Pluristem Therapeutics develops placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries and hematologic conditions. Co.'s product candidates include: Placenta expanded (PLX)-peripheral arterial disease, which is used in recovery following surgery for hip fracture, in Acute Respiratory Distress Syndrome associated with COVID-19 and Intermittent Claudication, and used in for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease; and PLX-R18, which is used in incomplete hematopoietic recovery following hematopoietic cell transplantation and Acute Radiation Syndrome following or before exposure to massive radiation. The PSTI stock yearly return is shown above.
The yearly return on the PSTI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PSTI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|